Proton Pump Inhibitor
PPI medications were made to combat acid reflux as well as other related issues by inhibiting its cause rather than curing its symptoms. The main problem associated with acid reflux is the overproduction of stomach acid.
- Headache (may be severe)
- Sleep Problems (insomnia)
Everything You Must Know About Proton Pump Inhibitor
Proton Pump Inhibitor Lawsuit Brief
Proton pump inhibitors prevent this by directly impacting on the system that’s responsible for controlling this process.
PPIs block the function of the gastric proton pump irreversibly, preventing acid secretion and consequently eliminating reflux symptoms.
Common Types Of PPI Brands
Several PPI brands, as well as manufacturers, have been implicated in the MDL. They incorporate prescription drugs like Nexium, Dexilant, Protonix, Prisolec, and Prevacid as well as other OTC (over-the-counter) drugs like Prevacid 24HR, Prisolec OTC, and Nexium 24HR.
All cases featured in the MDL claim the medications, utilized for controlling stomach acid, triggered serious side effects that damaged the kidneys. Litigations involving Prisolec, for instance, claim that AstraZeneca was aware of the kidney risks as from 2004, but didn’t warn patients regarding the risks for over 10 years.
Some of the kidney injuries claimed in these lawsuits, include:
- Kidney failure
- Acute interstitial nephritis (AIN)
- Kidney disease
- Kidney injury
- Kidney Injury Lawsuits Consolidated
The Main Problems Associated With Proton Pump Inhibitors
AstraZeneca, Pfizer, and Takeda are some of the biggest companies involved in the manufacture of these proton pump inhibitor drugs. The complainants claim that the firms failed to adequately warn patients about the risks associated with Prevacid, Prisolec, PPIs, and Nexium.
Considering that the widespread consumption of PPIs as well as their defective nature, it’s likely that more claimants will be negatively affected by the medications. And similar actions are more likely to be filed at the federal courts in the near future.
America’s Judicial Panel on MDLs denied the Multidistrict Litigation request in February 2017. The panel argued that the litigation arose from the plaintiff’s claims that consuming PPIs might result in various forms of kidney injuries, but the mentioned defendants varied from one action to another and are probably competitors. Proctor & Gamble was sued for eight actions, Pfizer in two and Takeda in four. On the other hand, AstraZeneca was sued in over 37 actions.
Increased Number Of PPI-Related Lawsuits
Certain acid reflux medications referred to as proton pump inhibitors (PPIs) have been shown to cause potentially life-threatening side effects. Research shows that over 15 million American citizens take these medications on a frequent basis, that’s why lawsuits continue cropping up across the country.
In October 2016, several PPI users who had filed 6 lawsuits against the manufacturers of these drugs asked the federal judicial court to consolidate all the federal injury cases into one multidistrict litigation.
Similarly, 15 cases of asserting similar prerogatives were pending in twelve district courts. As of February 2017, the total number of federal-related lawsuits significantly increased, reaching 39. The plaintiffs claimed that they suffered and still continue to suffer from severe kidney injuries, including interstitial nephritis, renal failure, acute kidney injuries, as well as chronic kidney disease.
Talk With a Lawyer
Same Day Appointments are Available.